Cordis history

By 1960, Murphy had changed the business's name to the more distinctive Cordis ("of the heart"), a moniker that indicated the primary focus of the company's efforts.

Cordis introduced its first remotely programmable pacemaker in 1973 and launched improved electrodes (which make the actual connection to the heart muscle) mid-decade.

1974: The FDA issues a product advisory against Cordis.

At the same time, several competitors--including Intermedics, which had supplanted Cordis as number two in pacemakers in 1979--were reeling from a kickback scandal.

Cordis lost $8.3 million in 1981 and by that time had racked up $89 million in debt.

1983: The company's pacemakers are recalled.

Since its founding in 1984, H&F has invested in over 100 companies.

CFO Robert Strauss succeeded Weldon as president and CEO upon the latter's resignation in 1987.

CEO Strauss hoped to increase Cordis's share of the therapeutic catheter market from two percent in 1991 to 15 percent by mid-decade, but he faced daunting competition from well-established giants in the medical business, including market-leading Eli Lilly & Co. and Pfizer Inc.

By 1994, the company had captured ten percent of total United States angioplasty sales&mdash⁄ort of Strauss's ambitious goal, but an impressive expansion nonetheless.

1996: Cordis becomes a Johnson & Johnson subsidiary in a $1.8 billion stock swap.

In 1997, the company formed its Endovacular division to focus on vascular disease treatments.

In 2000, Cordis resolved another patent dispute, this time with Guidant Corp.

Forbes commented on J&J's falter in a 2001 article, claiming that the company had "angered doctors with high prices, ignored demands for better technology, and wrongly assumed its patents would stall rivals.

Dominique transformed the overall business in the region to a solution provider, making it the fastest-growing EMEA market in 2014.

Prior to two years of private consultancy, Gray served over eight years first as Vice President Legal, Compliance, and Business Development EMEAC and then as Associate General Counsel – International for St Jude Medical, which was acquired by Abbott Laboratories in 2017.